CSI Market
Sign In | Register

Impel Pharmaceuticals Inc (IMPL) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access IMPL Annual Cash Flow →
A period-by-period view of cash flow from Impel Pharmaceuticals Inc to Sep 30 2022 helps clarify how Sep 30 2023's cash position has changed over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Sep 30 2023)
9 Months 		(Jun 30 2023) (Mar 31 2023) (Dec 31 2022) (Sep 30 2022)
Operating Activities
Income-51.24
Depreciation & amortization0.85
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase-1.78
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation3.49
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants-0.20
Noncash Interest-
Operating Lease Expense1.19
Non Cash Interest Expense And Amortization Of Debt Discount And Issuance Costs5.30
Change In Fair Value Of Convertible Notes-
Long Lived Asset Impairment0.42
Derivative Gain Loss On Derivative Net-11.56
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable0.86
Increase (Decrease) in Accounts Payable-2.19
Increase (Decrease) in Accrued Liabilities-3.13
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-1.95
Other Working Capital-0.04
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-1.11
Discontinued operations0.00
Net Cash flow from Operating Activities-61.11
Investing Activities
Capital Expenditures-1.87
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-1.87
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings7.06
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.01
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Exercise Of Redeemable Convertible Preferred Stock Warrants-
Proceeds From Follow On Public Offering Net Of Issuance Costs-
Proceeds From Issuances Of Long Term Debt-
Proceeds From Paycheck Protection Program-
Repayment Of Paycheck Protection Program-
Payment Of Deferred Offering Cost-
Proceeds From Deferred Royalty Obligation Net Of Issuance Costs-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities7.07
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-62.98
Total Cash Flow-55.91
4 historic quarters locked

Sign in to unlock the full Impel Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About Impel Pharmaceuticals Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0000950170-23-063759

Figures are derived from filed reports and may be restated. Historical data is subject to revision.